A small cohort of children with OPG were similarly responsive to MEK inhibition (NCT01089101)54 but equivalent strategies in the malignant context (in MPNST) have so far shown only moderate efficacy in mouse models.55 Of note, it has been reported that the RTK MET is activated in some MPNSTs and that a mouse model recapitulating MET activation in MPNST is sensitive to MET inhibition;56 it would therefore be interesting to test a variety of MEK combination therapies such as dual MET–MEK inhibition in the context of MPNSTs.56 Here, MET is linked to malignant peripheral nerve sheath tumor.